A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Key Inclusion Criteria: Patients must meet the following criteria to enroll in this study: * Part 1 Documented diagnosis of ovarian cancer, endometrial cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, triple negative breast cancer, non-small cell lung cancer, or cholangiocarcinoma * Part 2 Ovarian Cancer or Endometrial Cancer * No other meaningful life-prolonging therapy option available * Must provide archival tumor tissue or a newly obtained tumor biopsy specimen prior to the first dose of ELU001 for folate receptor alpha (FRα) expression analysis. Previous FRα expression test results may be used in certain circumstances * Adequate organ function * Measurable disease, or in the absence of measurable disease, non-measurable disease as per Response evaluation criteria in solid tumors (RECIST) v1.1 * Part 1: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; Part 2: ECOG performance status of 0 or 1. * Recovered from previous surgeries * Agree to highly effective contraception, not to get pregnant, or for men, not father a child during study participation Key Exclusion Criteria: Patients who meet any of the following are not eligible to enroll in this study: * Clinically significant eye disorders * Taken any treatments that use the protein folate receptor alpha or FRα to work * Taken any other experimental treatments * History of significant cardiac issues or other cancers within 3 years. * Significant anemia, significan…